Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.77 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.64 |
| ▸ | F10 | P00742 | 1/20 | 0.64 |
| ▸ | PLG | P00747 | 1/20 | 0.64 |
| ▸ | PLAT | P00750 | 1/20 | 0.64 |
| ▸ | PROC | P04070 | 1/20 | 0.64 |
| ▸ | HPN | P05981 | 1/20 | 0.64 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.64 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.64 |
| ▸ | NQO2 | P16083 | 1/20 | 0.64 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.64 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.64 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506730 | 0.94 | F2 (0.68) | F2SLC22A2F10PLGPLAT | |
| SCHEMBL6781845 | 0.91 | NQO2 (0.65) | F2SLC22A2F10PLGPLAT | |
| SCHEMBL506573 | 0.90 | F2 (0.80) | F2SLC22A2F10PLGPLAT | |
| Oxalic Acid SCHEMBL13740918 | 0.88 | F2 (0.78) | F2SLC22A2F10PLGPLAT | |
| SCHEMBL6778883 | 0.88 | F2 (0.65) | F2SLC22A2F10PLGPLAT | |
| SCHEMBL505887 | 0.87 | F2 (1.00) | F2SLC22A2F10PLGPLAT | |
| SCHEMBL6780096 | 0.87 | NQO2 (0.60) | F2SLC22A2F10PLGPLAT | |
| SCHEMBL20211338 | 0.87 | F2 (0.76) | F2SLC22A2F10PLGPLAT | |
| SCHEMBL6779012 | 0.87 | F2 (0.61) | F2SLC22A2F10PLGPLAT | |
| SCHEMBL6781191 | 0.86 | F2 (0.64) | F2SLC22A2F10PLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3195876-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-3195876-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-2525812-B1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INT (DE) | 2017-01-18 | — | — | EP | disclosed |
| EP-2525812-B1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INT (DE) | 2017-01-18 | — | — | EP | disclosed |
| US-20150210778-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INT (DE) | 2015-07-30 | — | — | US | disclosed |
| US-20150210778-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INT (DE) | 2015-07-30 | — | — | US | disclosed |
| US-20150210778-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INT (DE) | 2015-07-30 | — | — | US | disclosed |
| US-9034822-B2 | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds | BOEHRINGER IGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034822-B2 | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds | BOEHRINGER IGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034822-B2 | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds | BOEHRINGER IGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8486398-B2 | Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8486398-B2 | Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8486398-B2 | Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20120276123-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-01 | — | — | US | disclosed |
| WO-2012130834-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012130834-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-04 | — | — | WO | disclosed |
| US-20120027780-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120027780-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120027780-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011089183-A2 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210778-A1 | ANTICOAGULANT ANTIDOTES | SERPINC1, KCNH1, ANTXR2 | F2 6/4885SLC22A2 3620/4885F10 27/4885 |
| US-20120027780-A1 | ANTICOAGULANT ANTIDOTES | SERPINC1, KCNH1, ANTXR2 | F2 6/4885SLC22A2 3620/4885F10 27/4885 |
| US-20120276123-A1 | ANTICOAGULANT ANTIDOTES | SERPINC1, KCNH1, ANTXR2 | F2 6/4885SLC22A2 3620/4885F10 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.